Lytix Biopharma AS
The answer first
Does Lytix Biopharma beat the market?
No, Lytix Biopharma has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 16% of Nordic stocks
- Quality61
- Value2
- Trend34
No. 143 of 195 in healthcare
Max for seven days
Follow Lytix Biopharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Lytix Biopharma
Your first answer is free, no account needed.
Do you own Lytix Biopharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Lytix Biopharma and a few more. Free, no card.
Super Stock+46.4%In short
- Lytix Biopharma has fallen 21.6% over the past year, including dividends.
- Overall, Lytix Biopharma ranks better than 16% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 74.8%. The price is 57.0% below its peak now.
What do analysts think of Lytix Biopharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 16% of Nordic stocks.
No. 143 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 105 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.03
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−109.2%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 184 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity7.2
- P/SPrice divided by sales925.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 100 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+3.9%
- 6 months−20.4%
- 9 months−12.7%
- 12 months−21.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Lytix Biopharma
Lytix Biopharma AS is a company in healthcare, listed on Oslo Børs. By market value, Lytix Biopharma is number 10 of 23 companies in healthcare on Oslo Børs. Lytix Biopharma has not paid a dividend in the past twelve months. Of the three measures in the ranking, Lytix Biopharma is strongest on quality, better than 61% of Nordic stocks. The next report from Lytix Biopharma is expected on 11 February 2027. The share trades in NOK. It has around 14 employees.
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc.


See the full analysis of Lytix Biopharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card